Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02584933 · ClinicalTrials.gov registry record · Phase 4
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
A Phase 4 study of ALK Positive Malignancies, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 4
- Development phase
- 233
- Enrollment target
- 20
- Study locations
NCT02584933 is a Phase 4 study of ALK Positive Malignancies that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 233 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT02584933, a Phase 4 study of ALK Positive Malignancies, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 233 participants
- Enrollment target
- 20
- Study locations
Study Summary
The rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a Novartis-sponsored study and in the opinion of the investigator, would benefit from continued treatment with ceritinib.
Conditions Studied
Interventions
- DRUG ceritinib
Study Locations (20)
Other
- Novartis Investigative Site - Auckland
- Novartis Investigative Site - Leuven
- Novartis Investigative Site - Sofia
- Novartis Investigative Site - Beijing
- Novartis Investigative Site - Guangzhou
- Novartis Investigative Site - Montería
- Novartis Investigative Site - Brno
São Paulo
- Novartis Investigative Site - Barretos
- Novartis Investigative Site - São Paulo
Guangdong
- Novartis Investigative Site - Guangzhou
- Novartis Investigative Site - Guangzhou
Arkansas
- Highlands Oncology Group - Fayetteville
California
- Loma Linda University - Loma Linda
Colorado
- University of Colorado Cancer Center - Aurora
Maryland
- Maryland Oncology Hematology P A - Rockville
New Jersey
- Essex Oncology of North Jersey PA - Belleville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2015-12-11 |
| Est. Completion | 2027-06-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02584933
The ClinicalTrials.gov registry entry for NCT02584933 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 233 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with ALK Positive Malignancies appearing as the primary indexed condition, and to 1 intervention - of which ceritinib is the first listed.
NCT02584933 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, São Paulo, Guangdong.
Frequently Asked Questions
What is clinical trial NCT02584933 about?
NCT02584933 is a clinical study titled "Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study". The rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a Novartis-sponsored study and in the opinion of the investigator, would benefit from continued treatment with ceritinib.
What is the current status of trial NCT02584933?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 233 participants. The study started on 2015-12-11. Estimated completion is 2027-06-09.
What conditions does trial NCT02584933 study?
This clinical trial studies the following conditions: ALK Positive Malignancies.
What interventions are being tested in trial NCT02584933?
The interventions under investigation include: ceritinib (DRUG).
Who is sponsoring clinical trial NCT02584933?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02584933 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.